News Page
Published August 4, 2025
Reckitt Benckiser promited its Enfamil formula would make both families and investors smile. The bitter truth left everyone with tears. The stock tanked, infants got harmed, and now investors are crying foul with a class-action lawsuit.
From 2021 to twenty 2024, Reckitt said its Enfamil formula was pediatricians’ top choice, totally safe, and backed by science. This big claims boosted investor confidence. But behind the scenes, executives were sitting on studies linking the formula to deadly intestinal disease in babies and mounting legal risks.
Then, in July 2024, executives got a taste of their own medicine. Reports went public linking Enfamil to necrotizing entercolitis, a life-threatening condition. Massive lawsuits followed, leading to a huge verdict against Reckitt. Investors dumped their shares faster than spoiled milk, and Reckitt’s stock plummeted.
Now, more investors are joining the lawsuit.